Skip to content

US · FOCL · MEDICAL - DEVICES

EDAP TMS S.A. American Depositary Shares (FOCL) intrinsic value and stock valuation

$2.61as of 2026-11-21 · Mkt cap 228.27M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

EDAP TMS S.A. American Depositary Shares DCF and intrinsic value

InvestorsCraft values FOCL with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from FOCL’s statements →

EDAP TMS S.A. American Depositary Shares Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Vaulx-en-Velin, ARA 69120 focalone.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$70.8M+8.3% 5y CAGRd
20112025
Net income
-$-29.34M
20112025
Free cash flow
-$-21.4M
20112025
Total equity
$19.4M-9.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$70.8M$69.4M$65.3M$57.9M$52.1M
Operating income-$-25.21M-$-22.95M-$-22.1M-$-5.35M-$-3.51M
Net income-$-29.34M-$-20.57M-$-22.9M-$-3.08M$830K
EPSd-$-783.65K-$-551.62K-$-618.92K-$-89.56K$25.6K
Operating cash flow-$-16.46M-$-14.69M-$-15.87M-$-3.18M$5.26M
Capital expenditure-$-4.94M-$-1.42M-$-1.27M-$-640K-$-460K
Free cash flow-$-21.4M-$-16.12M-$-17.14M-$-3.82M$4.79M
Total assets$79M$89.1M$101.1M$107.9M$87.8M
Total debt$27.7M$14.4M$9.37M$10M$11.4M
Net debt$7.23M-$-16.48M-$-38.65M-$-57.36M-$-42.28M
Total equity$19.4M$42.4M$62.9M$76.5M$56.9M
Cash and short-term investments$20.5M$30.9M$48M$67.4M$53.7M
Income statement
20252024202320222021
Revenue$70.8M$69.4M$65.3M$57.9M$52.1M
Cost of revenue$40.7M$40.6M$38.9M$32.5M$30.3M
Gross profit$30.1M$28.7M$26.4M$25.4M$21.8M
Research and development expenses$10.1M$9.1M$8.21M$6.04M$5.62M
Selling, general and administrative expenses$45.2M$42.6M$40.3M$24.7M$19.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$55.3M$51.7M$48.5M$30.8M$25.3M
Cost and expenses$96M$92.3M$87.4M$63.3M$55.6M
Interest income$250K$860K$1.42M$420K$10K
Interest expense$790K$260K$250K$180K$60K
Depreciation and amortization$3.43M$2.8M$2.08M$1.72M$2.27M
Ebitda-$-25.05M-$-17.7M-$-20.31M-$-920K$2.66M
Operating income-$-25.21M-$-22.95M-$-22.1M-$-5.35M-$-3.51M
Total other income/expenses, net-$-4.06M$2.2M-$-540K$2.54M$3.83M
Income before tax-$-29.27M-$-20.75M-$-22.64M-$-2.81M$330K
Income tax expense$70K-$-180K$250K$270K-$-500K
Net income-$-29.34M-$-20.57M-$-22.9M-$-3.08M$830K
Weighted average shares outstanding$37.4M$37.3M$37M$34.4M$32.1M
Weighted average diluted shares outstanding$37.4M$37.3M$37M$34.4M$32.4M
Balance sheet
20252024202320222021
Cash and short-term investments$20.5M$30.9M$48M$67.4M$53.7M
Net receivables$22.6M$21M$21.3M$16M$13.8M
Inventory$12.8M$19.2M$16.7M$12.6M$8.53M
Total current assets$57.2M$72.4M$86.7M$96.6M$76.6M
Property, plant and equipment, net$13.5M$10.7M$9.05M$6.39M$5.88M
Goodwill and intangible assets$4.63M$3.62M$3.86M$3.35M$3.57M
Long-term investments$550K$0.00$0.00$0.00$0.00
Total non-current assets$21.8M$16.8M$14.4M$11.3M$11.2M
Total assets$79M$89.1M$101.1M$107.9M$87.8M
Accounts payable$11.8M$13.1M$12.4M$7.09M$6.27M
Short-term debt$9.35M$10.2M$5.71M$4.89M$4.27M
Deferred revenue$7.1M$6.88M$4.47M$4.32M$3.88M
Total current liabilities$37.1M$39.2M$30.5M$23.2M$20.4M
Long-term debt$18.3M$4.25M$3.66M$5.13M$7.11M
Deferred revenue, non-current$970K$370K$710K$280K$500K
Total non-current liabilities$22.4M$7.62M$7.77M$8.31M$10.5M
Capital lease obligations$2.43M$2.01M$1.45M$1.31M$1.5M
Total liabilities$59.6M$46.8M$38.3M$31.5M$30.9M
Common stock$6.07M$5.06M$5.36M$5.1M$4.99M
Retained earnings-$-128.62M-$-85.5M-$-70.2M-$-45.22M-$-44.85M
Accumulated other comprehensive income (loss)-$-8.34M-$-5.07M-$-4.96M-$-4.09M-$-4.08M
Total equity$19.4M$42.4M$62.9M$76.5M$56.9M
Total investments$550K$0.00$0.00$0.00$0.00
Total debt$27.7M$14.4M$9.37M$10M$11.4M
Net debt$7.23M-$-16.48M-$-38.65M-$-57.36M-$-42.28M
Cash flow statement
20252024202320222021
Net income-$-29.34M-$-20.57M-$-22.9M-$-3.08M$830K
Depreciation and amortization$3.43M$2.8M$2.08M$1.72M$2.27M
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$2.94M-$-2.12M-$-3.14M-$-4.54M$620K
Accounts receivable-$-570K-$-150K-$-5.31M-$-2.07M-$-120K
Inventory$6.87M-$-4.37M-$-4.55M-$-4.71M$200K
Accounts payable-$-2.97M$1.34M$5.71M$1.2M-$-40K
Net cash provided by operating activities-$-16.46M-$-14.69M-$-15.87M-$-3.18M$5.26M
Investments in property, plant and equipment-$-5.78M-$-1.67M-$-1.85M-$-790K-$-570K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-5.73M-$-4.46M-$-4.7M-$-2.5M-$-1.94M
Common stock issued$0.00$130K$280K$23.8M$25.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.64M$5.01M-$-980K$22.9M$24M
Net change in cash-$-10.44M-$-17.13M-$-19.36M$13.7M$23.4M
Cash at end of period$20.5M$30.9M$48M$67.4M$53.7M
Operating cash flow-$-16.46M-$-14.69M-$-15.87M-$-3.18M$5.26M
Capital expenditure-$-4.94M-$-1.42M-$-1.27M-$-640K-$-460K
Free cash flow-$-21.4M-$-16.12M-$-17.14M-$-3.82M$4.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About EDAP TMS S.A. American Depositary Shares

        EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycle—from development and marketing to manufacturing and servicing—of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.

        CEO
        Ryan Rhodes
        Employees
        289
        Beta
        -0.03

        Explore

        Frequently asked questions

        What is the intrinsic value of EDAP TMS S.A. American Depositary Shares (FOCL)?

        EDAP TMS S.A. American Depositary Shares (FOCL) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is FOCL undervalued?

        FOCL trades at a price of $2.61 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.